61 patents
Utility
Azetidinyl Pyrimidines and Uses Thereof
4 Jan 24
Provided herein are compounds useful as inhibitors of Janus kinase (JAK) proteins and in treating JAK-related diseases.
David Archer Ellis, Heeren M. Gordhan, Cynthia L. Lichorowic, Jill M. Sturdivant, Mitchell A. deLong
Filed: 29 Jun 23
Utility
Ophthalmic Pharmaceutical Compositions and Uses Thereof
27 Jul 23
Provided herein are ophthalmic pharmaceutical compositions comprising (1R,2S,5R)-2-isopropyl-N-(4-methoxyphenyl)-5-methylcyclohexane-1-carboxamide (WS-12) for effectively treating dry eye in a subject in need thereof, effectively reducing dry eye in a subject in need thereof, effectively reducing the likelihood of dry eye in a subject in need thereof, or for treating, preventing, or ameliorating signs or symptoms of dry eye in a subject in need thereof.
Anjali Joshi
Filed: 16 Dec 22
Utility
Ophthalmic compositions
25 Jul 23
The present disclosure provides an ophthalmic composition comprising 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or its pharmaceutically acceptable salts; about 0.01% weight/volume to about 1.0% weight/volume of a buffer; and about 0.01% weight/volume to about 10% weight/volume of a tonicity agent.
Cheng-Wen Lin, Casey Kopczynski, Mitchell A. deLong, Jill M. Sturdivant, Ramesh Krishnamoorthy
Filed: 24 Aug 22
Utility
Aryl Cyclopropyl-amino-isoquinolinyl Amide Compounds
20 Jul 23
Provided herein are amino isoquinolinyl amide and sulfonamide compounds that affect the function of kinases and other proteins in a cell and that are useful as therapeutic agents.
Mitchell A. deLong, Jill M. Sturdivant, Cynthia L. Lichorowic, Andriy Kornilov
Filed: 25 Aug 22
Utility
Isoquinoline-steroid conjugates and uses thereof
4 Jul 23
Provided herein are compounds and pharmaceutical compositions useful in modulating kinase activity, and related diseases.
Mitchell A. deLong, Eric Carlson, Casey Kopczynski, Jill M. Sturdivant, Cynthia Lichorowic
Filed: 4 Jun 21
Utility
Treatments
18 May 23
Described herein are compounds, combinations of compounds, compositions, formulations, and methods of treating viruses, viral load, and manifestations of viral infections.
Mitchell A. deLong, Kevin Stephen Carbajal
Filed: 8 Apr 21
Utility
Aryl Cyclopropyl-amino-isoquinolinyl Amide Compounds
27 Apr 23
Provided herein are arylcyclopropyl amino-isoquinoline amide compounds.
Mitchell A. deLong, Jill M. Sturdivant, Cynthia L. Lichorowic, Andriy Kornilov
Filed: 18 Apr 22
Utility
Dual mechanism inhibitors for the treatment of disease
4 Apr 23
Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition.
Mitchell A. deLong, Jill Marie Sturdivant, Susan M. Royalty
Filed: 28 Apr 21
Utility
Ophthalmic compositions
28 Feb 23
The present disclosure provides an ophthalmic composition comprising 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or its pharmaceutically acceptable salts; about 0.01% weight/volume to about 1.0% weight/volume of a buffer; and about 0.01% weight/volume to about 10% weight/volume of a tonicity agent.
Cheng-Wen Lin, Casey Kopczynski, Mitchell A. deLong, Jill M. Sturdivant, Ramesh Krishnamoorthy
Filed: 6 Jul 22
Utility
Heterobicyclic Carboxamides and Uses Thereof
5 Jan 23
Provided herein are heterobicyclic cyclopropanecarboxamide and heterobicyclic carboxamide compounds.
Mitchell A. deLong, Jill M. Sturdivant, Cynthia L. Lichorowic, Heeren M. Gordhan
Filed: 11 Sep 20
Utility
Ophthalmic Compositions
29 Dec 22
The present disclosure provides an ophthalmic composition comprising 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or its pharmaceutically acceptable salts; about 0.01% weight/volume to about 1.0% weight/volume of a buffer; and about 0.01% weight/volume to about 10% weight/volume of a tonicity agent.
Cheng-Wen Lin, Casey Kopczynski, Mitchell A. deLong, Jill M. Sturdivant, Ramesh Krishnamoorthy
Filed: 24 Aug 22
Utility
Implant Delivery Device
20 Oct 22
Implant delivery devices, methods of device assembly and methods of using those devices are presented where the delivery device uses an automatic implant delivery mechanism that eliminates variability in pusher wire speeds by providing a needle assembly having one or more implants positioned within a proximal end of a needle cannula, a dampener assembly and a shuttle assembly located within a housing along with the activation member which holds the shuttle assembly in cocked or pre-tensioned state.
Leo Anthony Trevino, Cheng Lin, Tyler Pegoraro, Stuart Williams, Thomas Shepard, Peter Andrew Smith, Matthew Charles Walker, Andrew John Corson, Thomas Ralph Blackburn, III, Stephen James Couse
Filed: 6 Apr 22
Utility
Ophthalmic Compositions
20 Oct 22
The present disclosure provides an ophthalmic composition comprising 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or its pharmaceutically acceptable salts; about 0.01% weight/volume to about 1.0% weight/volume of a buffer; and about 0.01% weight/volume to about 10% weight/volume of a tonicity agent.
Cheng-Wen Lin, Casey Kopczynski, Mitchell A. deLong, Jill M. Sturdivant, Ramesh Krishnamoorthy
Filed: 6 Jul 22
Utility
Ophthalmic Compositions
29 Sep 22
The present disclosure provides an ophthalmic composition comprising 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or its pharmaceutically acceptable salts; about 0.01% weight/volume to about 1.0% weight/volume of a buffer; and about 0.01% weight/volume to about 10% weight/volume of a tonicity agent.
Cheng-Wen Lin, Casey Kopczynski, Mitchell A. deLong, Jill M. Sturdivant, Ramesh Krishnamoorthy
Filed: 15 Jun 22
Utility
Aryl cyclopropyl-amino-isoquinolinyl amide compounds
30 Aug 22
Provided herein are amino isoquinolinyl amide and sulfonamide compounds that affect the function of kinases and other proteins in a cell and that are useful as therapeutic agents.
Mitchell A. deLong, Jill M. Sturdivant, Cynthia L. Lichorowic, Andriy Kornilov
Filed: 13 Sep 19
Utility
Ophthalmic compositions
19 Jul 22
The present disclosure provides an ophthalmic composition comprising 4-(3-amino-1-(isoquinolin-6-ylamino)-1-oxopropan-2-yl)benzyl 2,4-dimethylbenzoate or its pharmaceutically acceptable salts; about 0.01% weight/volume to about 1.0% weight/volume of a buffer; and about 0.01% weight/volume to about 10% weight/volume of a tonicity agent.
Cheng-Wen Lin, Casey Kopczynski, Mitchell A. deLong, Jill M. Sturdivant, Ramesh Krishnamoorthy
Filed: 30 Aug 17
Utility
Mono-(acid) Salts of 6-AMINOISOQUINOLINES and Uses Thereof
12 May 22
Provided herein are mono-(acid) salts of a compound of a Formulae provided herein.
Mitchell A. deLong, Jill M. Sturdivant, Cynthia L. Lichorowic, Cheng-Wen Lin
Filed: 14 Oct 21
Utility
Medical Implant
5 May 22
A medical implant is disclosed.
Thomas A. Shepard, Tyler Pegoraro, Stuart Williams, Sanjib Kumar Das, Leo Anthony Trevino, Cheng Li
Filed: 3 Nov 21
Utility
Aryl cyclopropyl-amino-isoquinolinyl amide compounds
26 Apr 22
Provided herein are arylcyclopropyl amino-isoquinoline amide compounds.
Mitchell A. deLong, Jill M. Sturdivant, Cynthia L. Lichorowic, Andriy Kornilov
Filed: 22 Jul 20
Utility
Combination Therapy
24 Mar 22
Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure.
Casey Kopczynski, Cheng-Wen Lin, Jill Marie Sturdivant, Mitchell A. deLong
Filed: 7 Dec 21